Penetration of diazepam and the non-peptide CCK antagonist, L-364, 718, into rat brain
- 1 October 1987
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 39 (10) , 863-864
- https://doi.org/10.1111/j.2042-7158.1987.tb05138.x
Abstract
Interest in the actions of the peptide cholecystokinin (CCK) has led to the design and synthesis of several non-peptide CCK antagonists, the most recent being that produced by Merck Sharp & Dohme and designated L-364, 718. This can be viewed as modified D-tryptophan linked to diazepam (1-methyl-3-(2-indoloyl)amino-5-phenyl-3H-1,4-benzodiazepin-2-one) 1.Keywords
This publication has 8 references indexed in Scilit:
- Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist.Proceedings of the National Academy of Sciences, 1986
- Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin.Proceedings of the National Academy of Sciences, 1986
- Blood—Brain Barrier Transport of Butanol and Water Relative to N-Isopropyl-p-Iodoamphetamine as the Internal ReferenceJournal of Cerebral Blood Flow & Metabolism, 1985
- Autoradiographic Determination of Regional Brain Glucose ContentJournal of Cerebral Blood Flow & Metabolism, 1983
- Methods for quantifying the transport of drugs across brain barrier systemsPharmacology & Therapeutics, 1981
- Immunochemical evidence of cholecystokinin-like peptides in brainNature, 1976
- Measurement of brain uptake of radiolabeled substances using a tritiated water internal standardBrain Research, 1970
- REGIONAL STUDIES OF CATECHOLAMINES IN THE RAT BRAIN‐IJournal of Neurochemistry, 1966